Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 1 / Phase 2	2026-04-17		NCT07496229

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Dizal Pharmaceuticals	20

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Chongqing Cancer Hospital	Chongqing	China	6
Fudan University Shanghai Cancer Center	Shanghai	China	128
Fujian Cancer Hospital	Fuzhou	China	55
Guangxi Medical University Cancer Hospital	Nanning	China	24
Henan Cancer Hospital	Zhengzhou	China	60
Henan Provincial People's Hospital	Zhengzhou	China	44
Nanjing Drum Tower Hospital	Nanjing	China	33
Shanxi Provincial Cancer Hospital	Taiyuan	China	16
Taizhou Hospital of Zhejiang Province	Taizhou	China	26
The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	China	41
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	54
West China Hospital of Sichuan University	Chengdu	China	68